CD4 level increases with CYT107 treatment (53).Having higher baseline CD4 may respond better for combinational anti-angiogenesis and immunotherapy in advanced triple-negative breast cancer (91).CD4 was not associated with distant disease-free survival (71). The gene discussed is CD4; the disease is triple-negative breast carcinoma.